公开(公告)号：US20220227773A1

公开(公告)日：2022-07-21

申请号：US17615300

申请日：2020-05-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD. ,  LIAN V NANTONG CO., LTD.

发明人： Jingshan SHEN ,  Yang HE ,  Chunhui WU ,  Feipu YANG ,  Zhen WANG ,  Junchi ZHANG ,  Fuqiang ZHU ,  Hongjian QIN

IPC分类号： C07D487/04 ,  C07D409/04 ,  C07D405/04 ,  C07D209/52

摘要： The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The compound provided in the present invention is useful for treating, preventing and/or controlling various nervous system disorders. The compound provided in the present invention modulates one or more monoamine transporters, inhibits the reuptake of endogenous monoamines such as dopamine, 5-hydroxytryptamine, and norepinephrine (e.g., from the synaptic cleft), and/or modulates the 5-HT3 receptor.

公开(公告)号：US20220204431A1

公开(公告)日：2022-06-30

申请号：US17611348

申请日：2020-05-15

申请人： TOPHARMAN SHANGHAI CO., LTD. ,  TOPHARMAN TANCHENG CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Jingshan SHEN ,  Xudong GONG ,  Fuqiang ZHU ,  Xiangrui JIANG ,  Yan ZHANG ,  Changliang SUN

IPC分类号： C07C37/16 ,  C07C35/21

摘要： Disclosed is a method for preparing cannabidiol and analogues thereof; the method is implemented by means of reacting a resorcinol derivative with menthyl-2,8-dien-1-ol or a derivative thereof. The method of the present invention has advantages of such as high chemical reaction selectivity and simple operation.

公开(公告)号：US20160102047A1

公开(公告)日：2016-04-14

申请号：US14975427

申请日：2015-12-18

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Qiang ZHANG ,  Rongxia ZHANG ,  Guanghui TIAN ,  Jianfeng LI ,  Fuqiang ZHU ,  Xiangrui JIANG

IPC分类号： C07C235/34 ,  C07C59/64 ,  C07C59/68

CPC分类号： C07C235/34 ,  C07C17/16 ,  C07C41/26 ,  C07C43/225 ,  C07C43/23 ,  C07C59/64 ,  C07C59/68 ,  C07C213/02 ,  C07C215/54 ,  C07C217/62 ,  C07C309/66 ,  C07C309/73 ,  C07C309/75 ,  C07D263/26 ,  C07D263/52 ,  Y02P20/582 ,  C07C22/04

摘要： The present invention relates to a (2R,3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process

摘要翻译： 本发明涉及式I所示的（2R，3R）-3-（3-取代苯基）-2-甲基正戊酰胺化合物及其制备方法，其中取代基如本说明书中所定义 ，本发明还涉及上述化合物用于制备他喷他多II或其药学上可接受的盐的用途，以及参与制备方法的中间体

公开(公告)号：US20220289684A1

公开(公告)日：2022-09-15

申请号：US17637637

申请日：2020-08-27

申请人： TOPHARMAN SHANGHAI CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIAMEDICA,CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN TANCHENG CO.,LTD.

发明人： Jingshan SHEN ,  Changliang SUN ,  Fuqiang ZHU ,  Junchi ZHANG ,  Rui LI

IPC分类号： C07D235/18 ,  C07C237/34

摘要： The present disclosure relates to a benzimidazole-substituted phenyl-n-butyramide-based compound and the preparation method thereof. The method of the present disclosure avoids nitration reaction and polyphosphoric acid cyclization reaction, and avoids the generation of a large amount of waste acid reaction solution from the source. The synthesis method embodied in the invention has the advantages of simplicity and high efficiency, mild conditions and few pollutants, etc., and is suitable to be developed as a green and sustainable production process.

公开(公告)号：US20200255421A1

公开(公告)日：2020-08-13

申请号：US16639394

申请日：2018-08-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

发明人： Yang HE ,  Xiangrui JIANG ,  Jianfeng LI ,  Yu WANG ,  Zhen WANG ,  Weiming CHEN ,  Fuqiang ZHU ,  Chunhui WU ,  Rongxia ZHANG ,  Jingshan SHEN ,  Hualiang JIANG

IPC分类号： C07D455/03 ,  A61P25/20 ,  C07D498/14

摘要： The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.